BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ: BMRN · Delayed Price · USD
86.71
-3.51 (-3.89%)
At close: Jan 18, 2022 4:00 PM
87.00
0.29 (0.33%)
Pre-market:Jan 19, 2022 7:42 AM EST
Market Cap15.92B
Revenue (ttm)1.85B
Net Income (ttm)15.92M
Shares Out183.59M
EPS (ttm)0.04
PE Ratio2,408.61
Forward PE46.95
Dividendn/a
Ex-Dividend Daten/a
Volume167
Open86.83
Previous Close90.22
Day's Range86.54 - 90.25
52-Week Range71.59 - 92.17
Beta0.49
AnalystsBuy
Price Target116.68 (+34.6%)
Earnings DateOct 27, 2021

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise ...

IndustryBiotechnology
IPO DateJul 23, 1999
CEOJean-Jacques Bienaime
Employees3,059
Stock ExchangeNASDAQ
Ticker SymbolBMRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 116.68, which is an increase of 34.56% from the latest price.

Price Target
$116.68
(34.56% upside)
Analyst Consensus: Buy

News

BioMarin CEO: There are biotech companies 'that probably should not be on the market today'

BioMarin CEO JJ Bienaimé joins Yahoo Finance Live's Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of biote...

3 days ago - Yahoo Finance

BioMarin CEO says study results for hemophilia gene therapy are as 'good as we could hope'

Jean-Jacques Bienaime, CEO and chairman of BioMarin Pharmaceutical, appeared on Tuesday's episode of "Mad Money," discussing trial results for the company's hemophilia gene therapy.

1 week ago - CNBC Television

Biomarin plans to resubmit its experimental gene therapy for hemophilia A to the FDA in the second quarter

Shares of BioMarin Pharmaceutical Inc. BMRN, -1.10% gained 5.6% in premarket trading on Monday, the day after the company announced promising data from a Phase 3 clinical study of its investigational ge...

1 week ago - Market Watch

BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A.  Annualized Blee...

1 week ago - Benzinga

BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults wi...

SAN RAFAEL, Calif., Jan. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec...

1 week ago - PRNewsWire

BioMarin to Participate in Two Virtual Investor Conferences in January

BioMarin to Present at Two Investor Conferences in January 2022 SAN RAFAEL, Calif., Jan. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, C...

2 weeks ago - PRNewsWire

BioMarin Update

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...

2 weeks ago - Newsfile Corp

4 Biotechs That Could Be Potential Takeover Targets in 2022

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attracti...

Other symbols:ADAPALNYBIIBCRSP
2 weeks ago - Zacks Investment Research

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsu...

NEW YORK, Dec. 22, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceu...

3 weeks ago - PRNewsWire

BMRN Final Deadline Today: Rosen, a Longstanding Law Firm, Encourages BioMarin Pharmaceutical Inc. Investors to Secur...

New York, New York--(Newsfile Corp. - December 22, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) bet...

4 weeks ago - Newsfile Corp

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in BioMarin Pharmaceutical Inc. with Losses of $100...

LOS ANGELES, Dec. 21, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMari...

4 weeks ago - PRNewsWire

BMRN FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure C...

New York, New York--(Newsfile Corp. - December 20, 2021) - WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) be...

4 weeks ago - Newsfile Corp

BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular...

SAN RAFAEL, Calif. and SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on dev...

1 month ago - PRNewsWire

BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors

SAN RAFAEL, Calif., Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former ...

1 month ago - PRNewsWire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses in Excess of $100K ...

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 20...

1 month ago - PRNewsWire

BioMarin Class Action Reminder

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...

1 month ago - Newsfile Corp

BMRN Investor Notice: Rosen, a Global and Leading Law Firm, Encourages BioMarin Pharmaceutical Inc. Investors with Lo...

New York, New York--(Newsfile Corp. - December 9, 2021) - WHY: New York, N.Y., December 9, 2021, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin...

1 month ago - Newsfile Corp

BioMarin Shareholder Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...

1 month ago - Newsfile Corp

UPCOMING DEADLINE: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Acti...

San Diego, California--(Newsfile Corp. - December 7, 2021) -  The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between...

1 month ago - Newsfile Corp

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Laws...

New York, New York--(Newsfile Corp. - December 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of B...

1 month ago - Newsfile Corp

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Importa...

NEW YORK, Dec. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 202...

1 month ago - PRNewsWire

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmac...

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceu...

1 month ago - Newsfile Corp

Rosen, National Trial Lawyers, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before...

New York, New York--(Newsfile Corp. - December 2, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) betw...

1 month ago - Newsfile Corp

BMRN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioMarin Pharmaceu...

New York, New York--(Newsfile Corp. - December 2, 2021) -  The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioMarin Pharmac...

1 month ago - Newsfile Corp

BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 22, 2021 in the Class Action Filed on ...

New York, New York--(Newsfile Corp. - December 2, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMR...

1 month ago - Newsfile Corp